Showing 1561-1570 of 5771 results for "".
- Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerabilityhttps://modernod.com/news/glaukos-announces-positive-results-for-idose-tr-exchange-trial-highlighting-favorable-safety-and-tolerability/2481346/Glaukos announced positive results for a prospective, multicenter clinical trial designed to evaluate the safety of the surgical exchange procedure for iDose TR (travoprost intraocular implant) in subjects who had previously been administered an iDose TR in the phase
- Keranova Announces Clinical Study Results for Robotic Laser Technologyhttps://modernod.com/news/keranova-announces-clinical-study-results-for-robotic-laser-technology/2481345/Keranova announced the finalization of the regulatory clinical studies of FemtoMatrix, its robotic laser technology. With the positive results, the company said it will now apply for CE marking for this new class of surgical equipment in cataract surgery. According to Ker
- Staar Surgical Announces Partnership with Actress Peyton Listhttps://modernod.com/news/staar-surgical-announces-partnership-with-actress-peyton-list/2481344/Staar Surgical announced a partnership with actress and beauty entrepreneur, Peyton List, to promote the EVO Implantable Collamer Lenses (EVO), which recevied FDA approval in 2022 for the correction of myopia with or without astigmatism. In December 2022, Ms. Li
- Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programshttps://modernod.com/news/glaukos-announces-positive-clinical-updates-for-several-corneal-health-pipeline-programs/2481343/Glaukos announced positive clinical updates for several of its corneal health pipeline programs, including the commencement of subject enrollment in a second phase 3 confirmatory trial for Epioxa (Epi-on), and initial results from the company’s phase 2a clinical trial for GLK-301
- Sifi Announces License Agreement with Avanzanite Bioscience for Acanthamoeba Keratitis Treatment Akantiorhttps://modernod.com/news/sifi-announces-license-agreement-with-avanzanite-bioscience-for-acanthamoeba-keratitis-treatment-akantior/2481340/Italy-based Sifi announced that it has partnered with Avanzanite Bioscience, a Dutch specialty pharmaceutical company, to exclusively commercialize and distribute Akantior (polihexanide) in 26 countries within the European Economic Area and Switzerland. Under the terms of the agreement,
- FCI Ophthalmics Announces Availability of EzyPor Polyethylene Orbital Implanthttps://modernod.com/news/fci-ophthalmics-announces-availability-of-ezypor-polyethylene-orbital-implant/2481336/FCI Ophthalmics announced the launch of EzyPor in the United States. EzyPor is a high density polyethylene orbital implant with a patented suturing platform, indicated for enucleation, evisceration, and secondary implantation. Ezyor is designed to have a smooth
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-data-from-ongoing-phase-12-trial-evaluating-low-dose-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481334/Viridian Therapeutics announced positive topline clinical data from the third, low dose cohort in its ongoing phase 1/2 clinical trial of VRDN-001, an anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). The company said it believes
- Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-pharma-announces-first-patient-enrolled-in-vega-2-pivotal-phase-3-trial-of-nyxol-in-presbyopia/2481333/Ocuphire Pharma announced the initiation of the VEGA-2 phase 3 pivotal trial with the first patient enrolled in late December. VEGA-2 is evaluating the efficacy and safety for two labels: Nyxol alone and Nyxol with adjunctive low-dose pilocarpine (LDP) therapy for presbyopia.
- Amber Ophthalmics Announces Positive Topline Phase 2 Data Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defect (PCED)https://modernod.com/news/amber-ophthalmics-announces-positive-topline-phase-2-data-evaluating-nexagon-for-the-treatment-of-persistent-corneal-epithelial-defect-pced/2481332/Amber Ophthalmics announced positive topline results from the phase 2 randomized, double-masked, vehicle-controlled clinical trial (EXPEDE) evaluating two topically administered concentrations of Nexagon (lufepirsen ophthalmic gel) for the treatment of persistent corneal epithelial defect (P
- Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmologyhttps://modernod.com/news/bausch-lomb-and-novaliq-announce-publication-of-pivotal-phase-3-data-on-nov03-perfluorohexyloctane-in-ophthalmology/2481330/Bausch + Lomb and Novaliq announced that Ophthalmology has published results from the pivotal phase 3 trial GOBI, which is one of two pivotal phase 3 trials for NOV03 (perfluorohexyloctane). NOV03 is being investigated to treat the signs and symptoms of dry eye disease (DED) as